Ascorbic acid 500mg / Zinc citrate 5mg modified-release capsules
Capsule
500mg
Oral
A six carbon compound related to glucose.
Active ingredients:
Ascorbic acid + Zinc
No active safety alerts
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Source: MHRA Products DatabaseOGL 3.0
Updated 3 months ago(16 Jan 2026)Safety monitoring data
Yellow Card reports
MHRA
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
EMA
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Show details
Part of the Redoxon brand family (generic: Ascorbic acid + Zinc)
1 products
MHRA licensed products
View all licensed products for Ascorbic acid + Zinc on the MHRA register
Show details
WHO defined daily dose (DDD)
200 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Show details
Ascorbic acid 1g effervescent tablets sugar free
Tablet
1g
Same therapeutic group
Ascorbic acid 7.5g/50ml solution for infusion vials
Infusion
7.5g/50ml
Same therapeutic group
Ascorbic acid 500mg effervescent tablets
Tablet
500mg
Same therapeutic group
Ascorbic acid 1g modified-release tablets
Tablet
1g
Same therapeutic group
Ascorbic acid 1.5g modified-release tablets
Tablet
1.5g
Same therapeutic group
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Show details
Loading prescribing data...
Clinical guidelines and formulary information
British National Formulary
Ascorbic acid + Zinc
BNF
Drug monograph — bnf.nice.org.ukSource: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Show details
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
Show details
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Show details
Searching UK clinical trials...
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
16 days
Mechanism
In humans, an exogenous source of ascorbic acid is required for collagen formati…
Food interactions
1 warning
Human targets
24 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
70%
70% to 90%
Half-life
16 days
16 days (3.4 hours in people who have excess levels of vitamin C)
Protein binding
25%
25%
Metabolism
Hepatic. Ascorbic acid is reversibly oxidised (by removal of the hydrogen from the enediol group of ascorbic acid) to dehydroascorbic acid.…
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Status:
Approved
Investigational
Nutraceutical
Small molecule
About this compound
A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.
Properties:
solid
Avg. mass: 176.12 Da
DrugBank indication
Used to treat vitamin C deficiency, scurvy, delayed wound and bone healing, urine acidification, and in general as an antioxidant. It has also been suggested to be an effective antiviral agent.
Also known as(187)
acide ascorbique
ácido ascórbico
Acidum ascorbicum
acidum ascorbinicum
Ascorbate
Ascorbic acid
Ascorbinsäure
L-(+)-ascorbic acid
Dosage forms(322)
Tablet, chewable (Oral) — 250 mg/1
Injection, solution (Intravenous) — 500 mg/5ml
Tablet (Oral) — 30 mg
Tablet, chewable (Oral)
Tablet, effervescent (Oral)
Liquid (Topical) — 39 g/100g
Liquid (Topical) — 39 g/70g
Injection (Intravenous) — 500 mg/1mL
Molecular properties(19)
Drug interactions(64)
Known interactions with other medications. Always consult a healthcare professional.
Aluminum hydroxide
Moderate
Ascorbic acid can cause an increase in the absorption of Aluminum hydroxide resulting in an increased serum concentration and potentially a worsening of adverse effects.
Bortezomib
Moderate
The therapeutic efficacy of Bortezomib can be decreased when used in combination with Ascorbic acid.
Deferoxamine
Unknown severity
The risk or severity of Cardiovascular Impairment can be increased when Ascorbic acid is combined with Deferoxamine.
Chlorpropamide
Moderate
Ascorbic acid may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.
Mecamylamine
Moderate
Ascorbic acid may increase the excretion rate of Mecamylamine which could result in a lower serum level and potentially a reduction in efficacy.
Cyclosporine
Unknown severity
The serum concentration of Cyclosporine can be decreased when it is combined with Ascorbic acid.
Chlorotrianisene
Unknown severity
The serum concentration of Ascorbic acid can be decreased when it is combined with Chlorotrianisene.
The serum concentration of Ascorbic acid can be decreased when it is combined with Estrone.
Dienestrol
Unknown severity
The serum concentration of Ascorbic acid can be decreased when it is combined with Dienestrol.
Polyestradiol phosphate
Unknown severity
The serum concentration of Ascorbic acid can be decreased when it is combined with Polyestradiol phosphate.
The serum concentration of Ascorbic acid can be decreased when it is combined with Mestranol.
Quinestrol
Unknown severity
The serum concentration of Ascorbic acid can be decreased when it is combined with Quinestrol.
The serum concentration of Ascorbic acid can be decreased when it is combined with Hexestrol.
Synthetic Conjugated Estrogens, A
Unknown severity
The serum concentration of Ascorbic acid can be decreased when it is combined with Synthetic Conjugated Estrogens, A.
Synthetic Conjugated Estrogens, B
Unknown severity
The serum concentration of Ascorbic acid can be decreased when it is combined with Synthetic Conjugated Estrogens, B.
The serum concentration of Ascorbic acid can be decreased when it is combined with Zeranol.
The serum concentration of Ascorbic acid can be decreased when it is combined with Equol.
Epimestrol
Unknown severity
The serum concentration of Ascorbic acid can be decreased when it is combined with Epimestrol.
The serum concentration of Ascorbic acid can be decreased when it is combined with Tibolone.
Promestriene
Unknown severity
The serum concentration of Ascorbic acid can be decreased when it is combined with Promestriene.
Methallenestril
Unknown severity
The serum concentration of Ascorbic acid can be decreased when it is combined with Methallenestril.
The serum concentration of Ascorbic acid can be decreased when it is combined with Moxestrol.
Esterified estrogens
Unknown severity
The serum concentration of Ascorbic acid can be decreased when it is combined with Esterified estrogens.
Estrone sulfate
Unknown severity
The serum concentration of Ascorbic acid can be decreased when it is combined with Estrone sulfate.
Biochanin A
Unknown severity
The serum concentration of Ascorbic acid can be decreased when it is combined with Biochanin A.
Formononetin
Unknown severity
The serum concentration of Ascorbic acid can be decreased when it is combined with Formononetin.
Diethylstilbestrol
Unknown severity
The serum concentration of Ascorbic acid can be decreased when it is combined with Diethylstilbestrol.
Conjugated estrogens
Unknown severity
The serum concentration of Ascorbic acid can be decreased when it is combined with Conjugated estrogens.
The serum concentration of Ascorbic acid can be decreased when it is combined with Estradiol.
Ethinylestradiol
Unknown severity
The serum concentration of Ascorbic acid can be decreased when it is combined with Ethinylestradiol.
The serum concentration of Ascorbic acid can be decreased when it is combined with Estriol.
Estradiol acetate
Unknown severity
The serum concentration of Ascorbic acid can be decreased when it is combined with Estradiol acetate.
Estradiol benzoate
Unknown severity
The serum concentration of Ascorbic acid can be decreased when it is combined with Estradiol benzoate.
Estradiol cypionate
Unknown severity
The serum concentration of Ascorbic acid can be decreased when it is combined with Estradiol cypionate.
Estradiol valerate
Unknown severity
The serum concentration of Ascorbic acid can be decreased when it is combined with Estradiol valerate.
The serum concentration of Ascorbic acid can be decreased when it is combined with Estetrol.
Amphetamine
Unknown severity
The serum concentration of Amphetamine can be decreased when it is combined with Ascorbic acid.
Phentermine
Unknown severity
The serum concentration of Phentermine can be decreased when it is combined with Ascorbic acid.
Benzphetamine
Unknown severity
The serum concentration of Benzphetamine can be decreased when it is combined with Ascorbic acid.
Diethylpropion
Unknown severity
The serum concentration of Diethylpropion can be decreased when it is combined with Ascorbic acid.
Lisdexamfetamine
Unknown severity
The serum concentration of Lisdexamfetamine can be decreased when it is combined with Ascorbic acid.
Mephentermine
Unknown severity
The serum concentration of Mephentermine can be decreased when it is combined with Ascorbic acid.
The serum concentration of MMDA can be decreased when it is combined with Ascorbic acid.
Midomafetamine
Unknown severity
The serum concentration of Midomafetamine can be decreased when it is combined with Ascorbic acid.
2,5-Dimethoxy-4-ethylamphetamine
Unknown severity
The serum concentration of 2,5-Dimethoxy-4-ethylamphetamine can be decreased when it is combined with Ascorbic acid.
Brolamfetamine
Unknown severity
The serum concentration of 4-Bromo-2,5-dimethoxyamphetamine can be decreased when it is combined with Ascorbic acid.
Tenamfetamine
Unknown severity
The serum concentration of Tenamfetamine can be decreased when it is combined with Ascorbic acid.
Chlorphentermine
Unknown severity
The serum concentration of Chlorphentermine can be decreased when it is combined with Ascorbic acid.
Methylenedioxyethamphetamine
Unknown severity
The serum concentration of Methylenedioxyethamphetamine can be decreased when it is combined with Ascorbic acid.
Dextroamphetamine
Unknown severity
The serum concentration of Dextroamphetamine can be decreased when it is combined with Ascorbic acid.
Showing 50 of 64 interactions
Food & lifestyle interactions
Advice
Avoid multivalent ions. Do not infuse with elemental compounds that can be reduced, such as copper.
How it works
Mechanism of action
In humans, an exogenous source of ascorbic acid is required for collagen formation and tissue repair by acting as a cofactor in the posttranslational formation of 4-hydroxyproline in -Xaa-Pro-Gly- sequences in collagens and other proteins. Ascorbic acid is reversibly oxidized to dehydroascorbic acid in the body. These two forms of the vitamin are believed to be important in oxidation-reduction reactions. The vitamin is involved in tyrosine metabolism, conversion of folic acid to folinic acid, carbohydrate metabolism, synthesis of lipids and proteins, iron metabolism, resistance to infections, and cellular respiration.
Pharmacodynamics
Ascorbic Acid (vitamin C) is a water-soluble vitamin indicated for the prevention and treatment of scurvy, as ascorbic acid deficiency results in scurvy. Collagenous structures are primarily affected, and lesions develop in bones and blood vessels. Administration of ascorbic acid completely reverses the symptoms of ascorbic acid deficiency.
Pharmacokinetics
How the body processes this drug — absorption, distribution, metabolism, and elimination
Absorption
70% to 90%
Half-life
16 days (3.4 hours in people who have excess levels of vitamin C)
Protein binding
25%
Metabolism
Hepatic. Ascorbic acid is reversibly oxidised (by removal of the hydrogen from the enediol group of ascorbic acid) to dehydroascorbic acid. The two forms found in body fluids are physiologically active.
Some ascorbic acid is metabolized to inactive compounds including ascorbic acid-2-sulfate and oxalic acid.
Some ascorbic acid is metabolized to inactive compounds including ascorbic acid-2-sulfate and oxalic acid.
Drug targets(24)
Proteins and enzymes this drug interacts with in the body
Solute carrier family 23 member 1
SLC23A1
modulator
Specific functiondehydroascorbic acid transmembrane transporter activity
Cellular location
Cell membrane
General function & pharmacology
Sodium:ascorbate cotransporter. Mediates electrogenic uptake of vitamin C, with a stoichiometry of 2 Na(+) for each ascorbate .
PMID:10556483 PMID:10556521 PMID:10631088 PMID:36749388
Has retained some ancestral activity toward nucleobases such as urate, an oxidized purine. Low-affinity high-capacity sodium:urate cotransporter, may regulate serum urate levels by serving as a renal urate re-absorber PMID:36749388
PMID:10556483 PMID:10556521 PMID:10631088 PMID:36749388
Has retained some ancestral activity toward nucleobases such as urate, an oxidized purine. Low-affinity high-capacity sodium:urate cotransporter, may regulate serum urate levels by serving as a renal urate re-absorber PMID:36749388
Solute carrier family 23 member 2
SLC23A2
modulator
Specific functionL-ascorbate
Cellular location
Cell membrane
General function & pharmacology
Sodium/ascorbate cotransporter .
PMID:10471399 PMID:10556521
Mediates electrogenic uptake of vitamin C, with a stoichiometry of 2 Na(+) for each ascorbate PMID:10471399
PMID:10471399 PMID:10556521
Mediates electrogenic uptake of vitamin C, with a stoichiometry of 2 Na(+) for each ascorbate PMID:10471399
DNA
cleavage
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2
PLOD2
cofactor
Specific functioniron ion binding
Cellular location
Rough endoplasmic reticulum membrane
General function & pharmacology
Forms hydroxylysine residues in -Xaa-Lys-Gly- sequences in collagens. These hydroxylysines serve as sites of attachment for carbohydrate units and are essential for the stability of the intermolecular collagen cross-links
Phytanoyl-CoA dioxygenase, peroxisomal
PHYH
cofactor
Specific functioncarboxylic acid binding
Cellular location
Peroxisome
General function & pharmacology
Catalyzes the 2-hydroxylation of not only racemic phytanoyl-CoA and the isomers of 3-methylhexadecanoyl-CoA, but also a variety of other mono-branched 3-methylacyl-CoA esters (with a chain length of at least seven carbon atoms) and straight-chain acyl-CoA esters (with a chain length longer than four carbon atoms) .
PMID:10744784 PMID:12031666 PMID:12923223 PMID:9326939
Does not hydroxylate long and very long straight chain acyl-CoAs or 2-methyl- and 4-methyl-branched acyl-CoAs PMID:10744784 PMID:12923223
PMID:10744784 PMID:12031666 PMID:12923223 PMID:9326939
Does not hydroxylate long and very long straight chain acyl-CoAs or 2-methyl- and 4-methyl-branched acyl-CoAs PMID:10744784 PMID:12923223
Metabolizing enzymes(1)
Enzymes involved in drug metabolism — important for understanding drug interactions
Enzyme activity key
substrate
inhibitor
inducer
TXNRD1Thioredoxin reductase 1, cytoplasmic
substrate
Transporters(5)
Proteins that transport this drug across cell membranes
Solute carrier family 23 member 1
SLC23A1
substrate
Specific functiondehydroascorbic acid transmembrane transporter activity
Cellular location
Cell membrane
General function & pharmacology
Sodium:ascorbate cotransporter. Mediates electrogenic uptake of vitamin C, with a stoichiometry of 2 Na(+) for each ascorbate .
PMID:10556483 PMID:10556521 PMID:10631088 PMID:36749388
Has retained some ancestral activity toward nucleobases such as urate, an oxidized purine. Low-affinity high-capacity sodium:urate cotransporter, may regulate serum urate levels by serving as a renal urate re-absorber PMID:36749388
PMID:10556483 PMID:10556521 PMID:10631088 PMID:36749388
Has retained some ancestral activity toward nucleobases such as urate, an oxidized purine. Low-affinity high-capacity sodium:urate cotransporter, may regulate serum urate levels by serving as a renal urate re-absorber PMID:36749388
Solute carrier family 23 member 2
SLC23A2
substrate
Specific functionL-ascorbate
Cellular location
Cell membrane
General function & pharmacology
Sodium/ascorbate cotransporter .
PMID:10471399 PMID:10556521
Mediates electrogenic uptake of vitamin C, with a stoichiometry of 2 Na(+) for each ascorbate PMID:10471399
PMID:10471399 PMID:10556521
Mediates electrogenic uptake of vitamin C, with a stoichiometry of 2 Na(+) for each ascorbate PMID:10471399
Solute carrier family 2, facilitated glucose transporter member 1
SLC2A1
substrate
Specific functionD-glucose transmembrane transporter activity
Cellular location
Cell membrane
General function & pharmacology
Facilitative glucose transporter, which is responsible for constitutive or basal glucose uptake .
PMID:10227690 PMID:10954735 PMID:18245775 PMID:19449892 PMID:25982116 PMID:27078104 PMID:32860739
Has a very broad substrate specificity; can transport a wide range of aldoses including both pentoses and hexoses .
PMID:18245775 PMID:19449892
Most important energy carrier of the brain: present at the blood-brain barrier and assures the energy-independent, facilitative transport of glucose into the brain .
PMID:10227690
In association with BSG and NXNL1, promotes retinal cone survival by increasing glucose uptake into photoreceptors (By similarity). Required for mesendoderm differentiation (By similarity)
PMID:10227690 PMID:10954735 PMID:18245775 PMID:19449892 PMID:25982116 PMID:27078104 PMID:32860739
Has a very broad substrate specificity; can transport a wide range of aldoses including both pentoses and hexoses .
PMID:18245775 PMID:19449892
Most important energy carrier of the brain: present at the blood-brain barrier and assures the energy-independent, facilitative transport of glucose into the brain .
PMID:10227690
In association with BSG and NXNL1, promotes retinal cone survival by increasing glucose uptake into photoreceptors (By similarity). Required for mesendoderm differentiation (By similarity)
Solute carrier family 2, facilitated glucose transporter member 3
SLC2A3
substrate
Specific functionD-glucose binding
Cellular location
Cell membrane
General function & pharmacology
Facilitative glucose transporter .
PMID:26176916 PMID:32860739 PMID:9477959
Can also mediate the uptake of various other monosaccharides across the cell membrane .
PMID:26176916 PMID:9477959
Mediates the uptake of glucose, 2-deoxyglucose, galactose, mannose, xylose and fucose, and probably also dehydroascorbate .
PMID:26176916 PMID:9477959
Does not mediate fructose transport .
PMID:26176916 PMID:9477959
Required for mesendoderm differentiation (By similarity)
PMID:26176916 PMID:32860739 PMID:9477959
Can also mediate the uptake of various other monosaccharides across the cell membrane .
PMID:26176916 PMID:9477959
Mediates the uptake of glucose, 2-deoxyglucose, galactose, mannose, xylose and fucose, and probably also dehydroascorbate .
PMID:26176916 PMID:9477959
Does not mediate fructose transport .
PMID:26176916 PMID:9477959
Required for mesendoderm differentiation (By similarity)
Solute carrier family 2, facilitated glucose transporter member 4
SLC2A4
substrate
Specific functionD-glucose transmembrane transporter activity
Cellular location
Cell membrane
General function & pharmacology
Insulin-regulated facilitative glucose transporter, which plays a key role in removal of glucose from circulation. Response to insulin is regulated by its intracellular localization: in the absence of insulin, it is efficiently retained intracellularly within storage compartments in muscle and fat cells. Upon insulin stimulation, translocates from these compartments to the cell surface where it transports glucose from the extracellular milieu into the cell
Carriers(1)
Proteins that carry this drug through the body
Albumin
ALB
binder
Specific functionantioxidant activity
Cellular location
Secreted
General function & pharmacology
Binds water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs (Probable). Its main function is the regulation of the colloidal osmotic pressure of blood (Probable). Major zinc transporter in plasma, typically binds about 80% of all plasma zinc .
PMID:19021548
Major calcium and magnesium transporter in plasma, binds approximately 45% of circulating calcium and magnesium in plasma (By similarity).
Potentially has more than two calcium-binding sites and might additionally bind calcium in a non-specific manner (By similarity). The shared binding site between zinc and calcium at residue Asp-273 suggests a crosstalk between zinc and calcium transport in the blood (By similarity). The rank order of affinity is zinc > calcium > magnesium (By similarity).
Binds to the bacterial siderophore enterobactin and inhibits enterobactin-mediated iron uptake of E.coli from ferric transferrin, and may thereby limit the utilization of iron and growth of enteric bacteria such as E.coli .
PMID:6234017
Does not prevent iron uptake by the bacterial siderophore aerobactin PMID:6234017
PMID:19021548
Major calcium and magnesium transporter in plasma, binds approximately 45% of circulating calcium and magnesium in plasma (By similarity).
Potentially has more than two calcium-binding sites and might additionally bind calcium in a non-specific manner (By similarity). The shared binding site between zinc and calcium at residue Asp-273 suggests a crosstalk between zinc and calcium transport in the blood (By similarity). The rank order of affinity is zinc > calcium > magnesium (By similarity).
Binds to the bacterial siderophore enterobactin and inhibits enterobactin-mediated iron uptake of E.coli from ferric transferrin, and may thereby limit the utilization of iron and growth of enteric bacteria such as E.coli .
PMID:6234017
Does not prevent iron uptake by the bacterial siderophore aerobactin PMID:6234017
Biological pathways(17)
metabolic
Involved compounds
Oxogluric acid,1,2-Dihydroxybenzene,2-(3,4-Dihydroxyphenyl)Acetic Acid,Homogentisic acid,4-Hydroxyphenylpyruvic acid,Acetoacetic acid,Calcium,Dopamine,Epinephrine,Flavin adenine dinucleotide,Iron,Aspartic acid,Glutamic acid,Tyrosine,Levodopa,Magnesium cation,Maleic acid,Methylamine,NADH,Norepinephrine,Pyridoxal phosphate,Pyrroloquinoline Quinone,Ademetionine,Sapropterin,Ascorbic acid,Zinc
metabolic
disease
Involved compounds
Oxogluric acid,1,2-Dihydroxybenzene,2-(3,4-Dihydroxyphenyl)Acetic Acid,Homogentisic acid,4-Hydroxyphenylpyruvic acid,Acetoacetic acid,Calcium,Dopamine,Epinephrine,Flavin adenine dinucleotide,Iron,Aspartic acid,Glutamic acid,Tyrosine,Levodopa,Magnesium cation,Maleic acid,Methylamine,NADH,Norepinephrine,Pyridoxal phosphate,Pyrroloquinoline Quinone,Ademetionine,Sapropterin,Ascorbic acid,Zinc
disease
Involved compounds
Oxogluric acid,1,2-Dihydroxybenzene,2-(3,4-Dihydroxyphenyl)Acetic Acid,Homogentisic acid,4-Hydroxyphenylpyruvic acid,Acetoacetic acid,Calcium,Dopamine,Epinephrine,Flavin adenine dinucleotide,Iron,Aspartic acid,Glutamic acid,Tyrosine,Levodopa,Magnesium cation,Maleic acid,Methylamine,NADH,Norepinephrine,Pyridoxal phosphate,Pyrroloquinoline Quinone,Ademetionine,Sapropterin,Ascorbic acid,Zinc
disease
Involved compounds
Oxogluric acid,1,2-Dihydroxybenzene,2-(3,4-Dihydroxyphenyl)Acetic Acid,Homogentisic acid,4-Hydroxyphenylpyruvic acid,Acetoacetic acid,Calcium,Dopamine,Epinephrine,Flavin adenine dinucleotide,Iron,Aspartic acid,Glutamic acid,Tyrosine,Levodopa,Magnesium cation,Maleic acid,Methylamine,NADH,Norepinephrine,Pyridoxal phosphate,Pyrroloquinoline Quinone,Ademetionine,Sapropterin,Ascorbic acid,Zinc
Involved compounds
Oxogluric acid,1,2-Dihydroxybenzene,2-(3,4-Dihydroxyphenyl)Acetic Acid,Homogentisic acid,4-Hydroxyphenylpyruvic acid,Acetic acid,Acetoacetic acid,Adenosine phosphate,ATP,Calcium,Pyrophosphoric acid,Disulfiram,Dopamine,Epinephrine,Ethanol,Flavin adenine dinucleotide,Iron,Aspartic acid,Glutamic acid,Tyrosine,Levodopa,Magnesium cation,Maleic acid,Mesoheme,Methylamine,NADH,Norepinephrine,Pyridoxal phosphate,Pyrroloquinoline Quinone,Ademetionine,Sapropterin,Ascorbic acid,Zinc
metabolic
disease
metabolic
Involved compounds
Oxogluric acid,1,2-Dihydroxybenzene,2-(3,4-Dihydroxyphenyl)Acetic Acid,Homogentisic acid,4-Hydroxyphenylpyruvic acid,Acetoacetic acid,Calcium,Dopamine,Epinephrine,Flavin adenine dinucleotide,Iron,Aspartic acid,Glutamic acid,Tyrosine,Levodopa,Magnesium cation,Maleic acid,Methylamine,NADH,Norepinephrine,Pyridoxal phosphate,Pyrroloquinoline Quinone,Ademetionine,Sapropterin,Ascorbic acid,Zinc
Involved compounds
Oxogluric acid,1,2-Dihydroxybenzene,2-(3,4-Dihydroxyphenyl)Acetic Acid,Homogentisic acid,4-Hydroxyphenylpyruvic acid,Acetoacetic acid,Calcium,Dopamine,Epinephrine,Flavin adenine dinucleotide,Iron,Aspartic acid,Glutamic acid,Tyrosine,Levodopa,Magnesium cation,Maleic acid,Methylamine,NADH,Norepinephrine,Pyridoxal phosphate,Pyrroloquinoline Quinone,Ademetionine,Sapropterin,Ascorbic acid,Zinc
Involved compounds
Oxogluric acid,1,2-Dihydroxybenzene,2-(3,4-Dihydroxyphenyl)Acetic Acid,Homogentisic acid,4-Hydroxyphenylpyruvic acid,Acetoacetic acid,Calcium,Dopamine,Epinephrine,Flavin adenine dinucleotide,Iron,Aspartic acid,Glutamic acid,Tyrosine,Levodopa,Magnesium cation,Maleic acid,Methylamine,NADH,Norepinephrine,Pyridoxal phosphate,Pyrroloquinoline Quinone,Ademetionine,Sapropterin,Ascorbic acid,Zinc
Scientific references(6)
Padayatty S.J., Katz A., Wang Y., Eck P., Kwon O., Lee J.H., Chen S., Corpe C., Dutta A., Dutta S.K., Levine M.
Vitamin C as an Antioxidant: Evaluation of Its Role in Disease Prevention.
Journal of the American College of Nutrition
200322(1):18-35. doi: 10.1080/07315724.2003.10719272
Meister A.
Glutathione-ascorbic acid antioxidant system in animals.
Journal of Biological Chemistry
1994269(13):9397-9400. doi: 10.1016/s0021-9258(17)36891-6
Englard S., Seifter S.
The Biochemical Functions of Ascorbic Acid.
Annual Review of Nutrition
19866(1):365-406. doi: 10.1146/annurev.nu.06.070186.002053
Banhegyi G., Mandl J.
The hepatic glycogenoreticular system.
Pathology & Oncology Research
20017(2):107-110. doi: 10.1007/bf03032575
Proctor P.
Similar Functions of Uric Acid and Ascorbate in Man ?.
Nature
1970228(5274):868-868. doi: 10.1038/228868a0
Korcok J., Dixon S.J., Lo T.C., Wilson J.X.
Differential effects of glucose on dehydroascorbic acid transport and intracellular ascorbate accumulation in astrocytes and skeletal myocytes.
Brain Research
2003993(1-2):201-207. doi: 10.1016/j.brainres.2003.09.016
ATC classification(4 codes)
ATC G01AD03
ATC A11GA01
ATC A11GB01
ATC S01XA15
Affected organisms(1)
Humans and other mammals
International brands(2)
Experimental properties(4)
Protein Data Bank entries(47)
Commercial products(2000)
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
International reference pricing
27 formulations
Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.
From $0.02/caplet
To $1.74/ml
CVS Pharmacy vitamin c 500 mg caplet
$0.02/caplet
CVS Pharmacy vitamin c 500 mg tablet
$0.02/tablet
Ra vitamin c 100 mg tablet
$0.02/tablet
Vicks vitamin c 60 mg drops
$0.02/tablet
Ra vitamin c cough drops
$0.03/tablet
Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.
Patent information
11 active patents, 2 expired
9326969
United States
Approved 3 May 2016 · Expires 10 Sept 2033
7y 5m
9707297
United States
Approved 18 Jul 2017 · Expires 10 Sept 2033
7y 5m
8999313
United States
Approved 7 Apr 2015 · Expires 10 Sept 2033
7y 5m
10016504
United States
Approved 10 Jul 2018 · Expires 10 Sept 2033
7y 5m
10918723
United States
Approved 16 Feb 2021 · Expires 10 Sept 2033
7y 5m
Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Knox C., Wilson M., Klinger C.M., et al
DrugBank 6.
0: the DrugBank Knowledgebase for 2024
Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
Wishart D.S., Feunang Y.D., Guo A.C., et al
DrugBank 5.
0: a major update to the DrugBank database for 2018
Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
Show earlier publications
Law V., Knox C., Djoumbou Y., et al
DrugBank 4.
0: shedding new light on drug metabolism
Nucleic Acids Res. 2014 Jan 142(1):D1091-7
Knox C., Law V., Jewison T., et al
DrugBank 3.
0: a comprehensive resource for 'omics' research on drugs
Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a knowledgebase for drugs, drug actions and drug targets.
Nucleic Acids Research
2008 Jan36(Database issue):D901-6
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a comprehensive resource for in silico drug discovery and exploration.
Nucleic Acids Research
2006 Jan 134(Database issue):D668-72
Source: go.drugbank.comCC BY-NC 4.0
Updated 27 days ago(8 Mar 2026)